Skip to main content

PatentVest Announces Strategic Intellectual Property Collaboration with Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

Written by Customer Service on . Posted in Public Companies.

Dallas, TX, March 11, 2026 (GLOBE NEWSWIRE) — PatentVest announced the completion of a strategic intellectual property engagement with Porosome Therapeutics, Inc., a biotechnology company developing a first-in-class therapeutic platform designed to restore cellular secretion mechanisms.

The collaboration focused on evaluating and strengthening Porosome Therapeutics’ intellectual property portfolio to support future partnerships, commercialization efforts, and capital strategy initiatives. PatentVest conducted a comprehensive IP portfolio audit, global patent landscape analyses, competitive benchmarking, and strategic partner assessment.

Porosome Therapeutics is advancing Porosome Reconstitution Platforms (PRPs), a novel approach to restore cells’ native secretory machinery. Unlike traditional therapies that suppress or modulate secretion pathways, the technology is designed to reconstruct the supramolecular porosome complex, the universal docking and fusion machinery responsible for cellular secretion.

The strategic analysis confirmed that Porosome Therapeutics occupies a distinct and defensible intellectual property position within the emerging field of secretion restoration technologies, with minimal direct competitive overlap in structural porosome reconstitution.

“The intellectual property landscape in cellular therapeutics is incredibly crowded, but Porosome Therapeutics has successfully carved out a highly defensible white space,” said Will Rosellini, CIPO of PatentVest. “Our analysis clearly shows that by focusing on the structural reconstitution of the porosome complex rather than traditional secretion modulation, they have secured a foundational patent portfolio. This distinct IP moat positions them exceptionally well for high-value strategic partnerships and long-term commercial success.”

“Working with PatentVest has provided valuable strategic insight into our intellectual property landscape and the broader competitive environment,” said Guillermo Marmol, CEO of Porosome Therapeutics. “Their analysis helped validate the strength of our IP portfolio and clarify how our platform is uniquely positioned within the field of secretion restoration technologies. This work supports our next phase of development as we pursue partnerships and expand our patent portfolio.”

As part of its ongoing innovation strategy, Porosome Therapeutics continues to expand its intellectual property portfolio with new filings covering organoid models, novel peptides, and small-molecule innovations designed to strengthen its proprietary platform further.

About Porosome Therapeutics

Porosome Therapeutics, Inc. is a biotechnology company developing therapies based on the restoration of cellular secretion mechanisms through Porosome Reconstitution Platforms (PRPs), with potential applications in diseases associated with dysfunctional secretion.

Work With PatentVest

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. Powered by a proprietary global IP database and a rigorous diligence methodology, PatentVest delivers actionable intelligence that reveals the structural advantages hidden beneath technology markets. 

For more information or inquiries, please contact info@patentvest.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.